NO20082386L - Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav - Google Patents

Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav

Info

Publication number
NO20082386L
NO20082386L NO20082386A NO20082386A NO20082386L NO 20082386 L NO20082386 L NO 20082386L NO 20082386 A NO20082386 A NO 20082386A NO 20082386 A NO20082386 A NO 20082386A NO 20082386 L NO20082386 L NO 20082386L
Authority
NO
Norway
Prior art keywords
ligands
egfr
vegf
methods
binding specificity
Prior art date
Application number
NO20082386A
Other languages
English (en)
Inventor
Haiqun Liu
Steve Holmes
Laurent S Jespers
Rudolf M T De Wildt
Armin Sepp
Olga Ignatovich
Roland Beckmann
Michael Steward
Malgorzata Pupecka
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of NO20082386L publication Critical patent/NO20082386L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SAMMENDRAG Det er beskrevet ligander som har bindingsspesifisitet for vaskulær endotel-vekstfaktor (VEGF), for epidermal vekstfaktor reseptor (EGFR) eller for VEGF og EGFR. Fremgangsmåter for anvendelse av disse ligandene er også beskrevet. Spesielt er anvendelse av disse ligandene for kreftterapi beskrevet.
NO20082386A 2005-12-06 2008-05-26 Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav NO20082386L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74299205P 2005-12-06 2005-12-06
US75835506P 2006-01-11 2006-01-11
PCT/GB2006/004559 WO2007066106A1 (en) 2005-12-06 2006-12-05 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor

Publications (1)

Publication Number Publication Date
NO20082386L true NO20082386L (no) 2008-08-27

Family

ID=37820653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082386A NO20082386L (no) 2005-12-06 2008-05-26 Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav

Country Status (13)

Country Link
US (2) US20100056439A1 (no)
EP (1) EP1966242A1 (no)
JP (1) JP2009518024A (no)
KR (1) KR20080077261A (no)
AU (1) AU2006323412A1 (no)
BR (1) BRPI0619463A2 (no)
CA (1) CA2632417A1 (no)
CR (1) CR10024A (no)
EA (1) EA013878B1 (no)
MA (1) MA30021B1 (no)
NO (1) NO20082386L (no)
TW (1) TW200804425A (no)
WO (1) WO2007066106A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
GB2468232B (en) * 2007-11-30 2012-10-24 Glaxo Group Ltd Antigen-bindng constructs
KR20100098697A (ko) * 2007-12-13 2010-09-08 글락소 그룹 리미티드 폐 전달을 위한 조성물
EA021967B1 (ru) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
CN102046207B (zh) 2008-03-31 2013-08-28 葛兰素集团有限公司 药物融合物和缀合物
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2010033249A2 (en) * 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
WO2010046337A2 (en) * 2008-10-21 2010-04-29 Domantis Limited Ligands that have binding specificity for dc-sign
EP2356147A1 (en) * 2008-11-26 2011-08-17 Glaxo Group Limited Polypeptides, antibody variable domains&antagonists
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2010094720A2 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
RU2011138951A (ru) 2009-02-23 2013-03-27 Сайтомкс Терапьютикс, Инк. Пропротеины и способы их применения
CA2763491A1 (en) * 2009-05-28 2010-12-02 Paul Andrew Hamblin Antigen-binding proteins
BR112012001681A2 (pt) * 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
BR112013003899A2 (pt) * 2010-08-20 2016-06-07 Glaxosmithkline Ip Dev Ltd domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente
US20130236467A1 (en) * 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
EP2777707A1 (en) 2013-03-11 2014-09-17 Wake Forest University Health Sciences Method of Treating Brain Tumors
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
PL3049439T3 (pl) * 2013-09-26 2020-07-13 Ablynx N.V. Bispecyficzne nanociała
CA2974192C (en) 2015-01-21 2024-02-20 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
JP6640232B2 (ja) * 2015-02-06 2020-02-05 ユニバーシティ オブ メリーランド，ボルチモア クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体
HUE051896T2 (hu) 2015-07-16 2021-03-29 Inhibrx Inc Multivalens és multispecifikus DR5-kötõ fúziós fehérjék
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
US11773172B2 (en) 2018-03-19 2023-10-03 WuXi Biologics Ireland Limited Anti-EGFR antibody polypeptide
EA202192654A1 (ru) * 2019-03-29 2021-12-30 Грин Кросс Корпорейшн Слитый белок, содержащий анти-мезотелин антитело, анти-cd3 антитело или анти-egfr антитело, биспецифическое или триспецифическое антитело, содержащие его, и их применения
US12043652B2 (en) 2020-08-28 2024-07-23 Trustees Of Boston University Engineered extracellular receptor constructs and uses thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699237B1 (en) * 1994-03-17 2003-02-19 MERCK PATENT GmbH Anti-egfr single-chain fvs and anti-egfr antibodies
ATE318143T1 (de) * 1996-10-25 2006-03-15 Gilead Sciences Inc Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe
DE122007000021I1 (de) * 1997-04-07 2007-05-24 Genentech Inc Anti-vefg Antibodies
JP2004529610A (ja) * 2000-10-13 2004-09-30 ユーエイビー リサーチ ファンデーション ヒト抗上皮増殖因子受容体一本鎖抗体
RU2295537C2 (ru) * 2000-10-20 2007-03-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
ES2315664T3 (es) * 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
ATE485307T1 (de) * 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR

Also Published As

Publication number Publication date
EA013878B1 (ru) 2010-08-30
US20100056439A1 (en) 2010-03-04
US20130041136A1 (en) 2013-02-14
BRPI0619463A2 (pt) 2013-01-08
AU2006323412A1 (en) 2007-06-14
CA2632417A1 (en) 2007-06-14
WO2007066106A1 (en) 2007-06-14
CR10024A (es) 2008-09-22
MA30021B1 (fr) 2008-12-01
EA200801172A1 (ru) 2008-12-30
EP1966242A1 (en) 2008-09-10
TW200804425A (en) 2008-01-16
JP2009518024A (ja) 2009-05-07
KR20080077261A (ko) 2008-08-21

Similar Documents

Publication Publication Date Title
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
NO20082960L (no) Ligander med bindingsspesifisitet for VEGF og/eller EGFR og fremgangsmater for anvendelse derav
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2007149482A3 (en) Xanthohumol based protein kinase modulation cancer treatment
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
MY160445A (en) Dual Variable Domain Immunoglobulins And Uses Thereof
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
NO20085422L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
NO20085421L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
DK1951759T3 (da) Anti-EGFR-antistoffer
EA200801430A1 (ru) Производные триазола
DK1782070T3 (da) Tumorassocieret antigenprofiler i cancerdiagnostik og immunterapi
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
ATE452149T1 (de) Modifizierte polyolefinwachse
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
NO20090333L (no) Fremgangsmater og preparater rettet mot hepsin